<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01237483</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2008-01</org_study_id>
    <nct_id>NCT01237483</nct_id>
  </id_info>
  <brief_title>Reirradiation and Erbitux in the HNSCC</brief_title>
  <official_title>A Phase II Study, Multicenter, to Evaluate the Efficacy and Safety of the Combination of Reirradiation - Erbitux in Subjects Previously Irradiated and With a Local Recurrent Inoperable Squamous Cell Cancer of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate in patients with cancer of the throat and&#xD;
      recurrent inoperable a different modality treatment consisting of radiation continuously for&#xD;
      5 weeks and half associated with a drug directed against a receptor on cell surfaces cancer,&#xD;
      called Erbitux ®.&#xD;
&#xD;
      The investigators hope with this shorter treatment (1.5 weeks less than the usual treatment)&#xD;
      to improve the antitumor efficacy without additional toxic side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hope with this treatment improved antitumor efficacy without additional toxic side&#xD;
      effects, while being shorter than 1.5 weeks of standard therapy. But this is an hypothesis we&#xD;
      can not meet the current state of knowledge, which justifies this study.&#xD;
&#xD;
      The main hypothesis is that this combination of reirradiation and Cetuximab give a relative&#xD;
      gain of 15% complete response rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Actual">July 5, 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main objective is to evaluate the complete response rate of the association re-irradiation - Erbitux ®.</measure>
    <time_frame>It will be measured by spiral CT scan or magnetic resonance imaging (MRI), 2 months after the end of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Head and Neck Cancer Squamous Cell</condition>
  <arm_group>
    <arm_group_label>Erbitux Radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Radiotherapy during 5 weeks and concurrent Erbitux once a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erbitux</intervention_name>
    <description>To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)</description>
    <arm_group_label>Erbitux Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with unresectable locoregional recurrence of squamous cell carcinoma in a&#xD;
             previously irradiated area (at least 75% of the volume of recidivism must be in an&#xD;
             area who have received at least 50 Gy)&#xD;
&#xD;
          -  The entire tumor volume can be included in a radiation field without the total dose to&#xD;
             the spinal cord more than 50 Gy (dose + dose earlier predicted)&#xD;
&#xD;
          -  Patient with recurrent or second location in the oral cavity, oropharynx, larynx,&#xD;
             hypopharynx, cervical lymph nodes or tissues, without distant metastases,&#xD;
&#xD;
          -  Minimum 12 months after the end of radiotherapy previous&#xD;
&#xD;
          -  WHO performance status: 0-1,&#xD;
&#xD;
          -  Evaluable disease by RECIST V.1.1.,&#xD;
&#xD;
          -  Age between 18 and 75 years&#xD;
&#xD;
          -  The patient may have received prior chemotherapy for relapse for more than five weeks,&#xD;
&#xD;
          -  The patient may have received cetuximab for the treatment of disease but not for the&#xD;
             first relapse,&#xD;
&#xD;
          -  Hematologic function: ANC ≥ 1500/mm3, Platelets ≥ 100000/mm3,&#xD;
&#xD;
          -  Normal renal function: serum creatinine ≤ 120 µmol/l and/or creatinine clearance &gt; 60&#xD;
             ml/min&#xD;
&#xD;
          -  Normal liver function: bilirubin &lt;1.5 x ULN, alkaline phosphatase and transaminases&#xD;
             &lt;2.5 x ULN,&#xD;
&#xD;
          -  Normal cardiac function, assessed clinically. History of cardiovascular disease&#xD;
             stabilized for over 12 months&#xD;
&#xD;
          -  Cons-Lack of medical indications in the proposed treatment,&#xD;
&#xD;
          -  The dosimetry of previous treatment should be available and the estimated dosimetry&#xD;
             must be performed to check the constraints,&#xD;
&#xD;
          -  All patients of childbearing age should receive effective contraception,&#xD;
&#xD;
          -  Membership of a social security system (or be a beneficiary of such a plan) under the&#xD;
             terms of the Act of August 9, 2004,&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumors of the nasal cavity and paranasal,&#xD;
&#xD;
          -  Tumors of other histological type,&#xD;
&#xD;
          -  Stage IV with distant metastases or multiple tumors,&#xD;
&#xD;
          -  Time after previous radiotherapy &lt;12 months,&#xD;
&#xD;
          -  Less than 75% of the volume of relapse who have previously received at least 50 Gy,&#xD;
&#xD;
          -  Any medical condition or general-cons would indicate the completion of treatment.&#xD;
             Systemic disease or uncontrolled infection,&#xD;
&#xD;
          -  History of cancer other than head and neck cancer, cutaneous basal cell, carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
          -  Any other concurrent anticancer therapy,&#xD;
&#xD;
          -  Patient receiving another molecule experimental&#xD;
&#xD;
          -  Pregnant, lactating or without contraception;&#xD;
&#xD;
          -  Persons deprived of liberty under guardianship&#xD;
&#xD;
          -  Inability to undergo medical test for geographical, social or psychological&#xD;
&#xD;
          -  Nasopharyngeal Neoplasms&#xD;
&#xD;
          -  Patients with active ischemic heart disease or previous myocardial infarction within&#xD;
             the last 12 months&#xD;
&#xD;
          -  Late toxicity dermal or subcutaneous related to previous irradiation of grade&gt; 2 in&#xD;
             the scale CTCAE V.4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent MARTIN, oncologist</last_name>
    <role>Study Director</role>
    <affiliation>Centre Guillaume Le Conquérant, 76600 Le Havre, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claude TUCHAIS, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Paul Papin, 49933 Angers, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sauveur Marc ALFONSI, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Sainte Catherine, 84082 Avignon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xu Sh SUN, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Jean Minoz, 25030 Besançon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique DE RAUCOURT, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse, 14076 Caen, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel LAPEYRE, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin, 63011 Clermond-Ferrand, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe MAINGON, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre G-F Leclerc, 21079 Dijon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muriel GARCIA-RAMIREZ, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Robert Boulin, 33505 Libourne, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian SIRE, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital du Scorff, 56322 Lorient, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Séverine RACADOT, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Léon Bérard, 69373 Lyon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Véronique FAVREL, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Lyon Sud, 69495 Pierre-Benite, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Etienne BARDET, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre René Gauducheau, 44805 Nantes-St Herblain, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe LANG, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital de La Pitié Salpitrière, 75013 Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle TENNEVET, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Henri Becquerel, 76038 Rouen, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia BURBAN, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Armoricaine de Radiologie, 22015 St Brieuc, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier GALLOCHER, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur, 31300 Toulouse, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier GALLOCHER, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polyclinique du Parc, 31078 Toulouse, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yungan TAO, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy, 94805 Villejuif, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre BOISSELIER, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Val d'Aurelle 34298 Montpellier cedex</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédéric PEYRADE, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne 06189 NICE cedex 2</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie SALIOU, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique de l' Estuaire 44600 Pornichet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cédrik LAFOND, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Bernard 72000 Le Mans</affiliation>
  </overall_official>
  <overall_official>
    <last_name>René-Jean BENSADOUN, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU 86021 Poitiers cedex</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre COUTTE, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens sud 80004 Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hao QIU, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU 86000 Limoges</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florence HUGUET, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Tenon 75020 Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sébastien GUIHARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Paul Strauss 67065 Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xu Shan SUN, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de Belfort Montbéliard Bd du Maréchal Juin 25200 Montbéliard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours Cedex 09</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>November 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2010</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>reirradiation with Erbitux</keyword>
  <keyword>HNSCC</keyword>
  <keyword>local recurrent inoperable Squamous Cell Cancer of the Head and Neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

